MiNK Therapeutics

MiNK is at the 3D Tissue Models Summit in Boston, where Shanmugarajan Krishnan will share data from our allogeneic FAP-CAR-iNKT cell therapy in human organoid models of MSS colorectal cancer liver metastases. https://lnkd.in/e2JSpua

Yesterday Terese C. Hammond, MD presented data at the American Thoracic Society #ATS2024 Annual Meeting in San Diego, CA, showcasing the clinical activity of MiNK’s allogeneic iNKT cells in respiratory distress. Learn more: https://bit.ly/4bPoRie

This quarter we made significant strides across our iNKT cell programs, including generating clinical data from our agenT-797 program, strengthening our financial position, and advancing our innovative next-generation therapies. Read more in our Q1 report: https://bit.ly/3yrUjEN

Today we’ve announced a $5.8M in private placement financing to accelerate MiNK-215's clinical development and the appointment of a Board Observer. Learn more: https://bit.ly/3UHIcv7

#ICYMI - check out our presentation from #AACR2024 yesterday: https://lnkd.in/e6BFc7Ye Thank you to everyone who stopped by our poster session with Shanmugarajan Krishnan to hear new preclinical data on MiNK-215’s activity against colorectal cancer liver metastases. We enjoyed diving into the innovative potential of iNKT cell therapies to reshape the landscape of solid tumor cancer treatment. #CellTherapy #CancerResearch #iNKT #MiNK215

Today, we announced encouraging preclinical data from of MiNK-215, our IL-15 armored FAP-CAR-iNKT cell therapy at #AACR2024. Learn more about how MiNK-215 showcases potent anti-tumor activity against MSS colorectal cancer liver metastases in human organoid models here: https://bit.ly/3vQunlm #CellTherapy #MiNK215 #CancerResearch

We are thrilled to join oncology leaders in San Diego, CA for #AACR2024! Stop by our poster presentation today at 9:00 a.m. PST to hear exciting preclinical data on MiNK-215 in colorectal cancer liver metastases, presented by Shanmugarajan Krishnan. #CancerResearch #CellTherapy #AACR #MiNK215

Today MiNK announced results for the fourth quarter and year-end of 2023. Our year was marked by progress across our clinical programs, manufacturing capabilities, and research team, which continue to solidify MiNK’s leadership in the field of #iNKT cell therapy. Read more about the results and our plans for 2024: https://bit.ly/43uBFHR

Today we recognize and thank all the women who inspire, lead, and break barriers. MiNK is proud to #InspireInclusion with our dedicated team of female leaders who help pioneer our commitment to delivering #iNKT cell therapies for patients. #InternationalWomensDay #IWD2024

Stay tuned for MiNK’s upcoming presentation at #AACR 2024. On April 8 in San Diego, MiNK will present exciting preclinical data on MiNK-215, our IL-15 armored FAP-targeting CAR-iNKT cell therapy, demonstrating its unique potential against liver metastases in MSS colorectal cancer. Learn more about the data and presentation: https://bit.ly/4c5Y8yQ #iNKT #CellTherapy #ColorectalCancer #ColorectalCancerAwarenessMonth